flutamide has been researched along with Pancreatic Neoplasms in 12 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma." | 9.12 | Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. ( Agarwal, A; Chaudhary, A; Negi, SS, 2006) |
| "This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma." | 5.12 | Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. ( Agarwal, A; Chaudhary, A; Negi, SS, 2006) |
| "Flutamide is a potent antiandrogen widely used in clinical practice for patients with metastatic prostate cancer." | 2.68 | Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. ( Hilsenbeck, SG; Razvillas, B; Rothenberg, ML; Sharma, A; Sharma, JJ; Stephens, CD, 1997) |
| "Up-regulated PCDH1 promotes pancreatic cancer cell metastasis." | 1.91 | PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy. ( Chen, Y; Du, X; He, X; Ren, X; Tai, Y; Yi, X; Zou, X, 2023) |
| "Flutamide was administered in a dosage of 250mg 3 times daily." | 1.31 | Androgen receptor-blocking agents: potential role in pancreatic cancer. ( Greenway, BA, 2000) |
| "Previous reports have shown that pancreatic cancer was induced preferentially in male versus female azaserine-treated rats." | 1.27 | Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats. ( Brinck-Johnsen, T; Lhoste, EF; Longnecker, DS; Roebuck, BD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Du, X | 1 |
| Yi, X | 1 |
| Zou, X | 1 |
| Chen, Y | 1 |
| Tai, Y | 1 |
| Ren, X | 1 |
| He, X | 1 |
| Corrie, P | 1 |
| Mayer, A | 1 |
| Shaw, J | 1 |
| D'Ath, S | 1 |
| Blagden, S | 1 |
| Blesing, C | 1 |
| Price, P | 1 |
| Warner, N | 1 |
| Negi, SS | 1 |
| Agarwal, A | 1 |
| Chaudhary, A | 1 |
| Konduri, S | 1 |
| Schwarz, MA | 1 |
| Cafasso, D | 1 |
| Schwarz, RE | 1 |
| Sharma, JJ | 1 |
| Razvillas, B | 1 |
| Stephens, CD | 1 |
| Hilsenbeck, SG | 1 |
| Sharma, A | 1 |
| Rothenberg, ML | 1 |
| Greenway, BA | 2 |
| Bramhall, S | 1 |
| Buckels, J | 1 |
| Wigmore, SJ | 1 |
| Fearon, KC | 1 |
| Garden, OJ | 1 |
| Wasan, HS | 1 |
| Lhoste, EF | 1 |
| Roebuck, BD | 1 |
| Brinck-Johnsen, T | 1 |
| Longnecker, DS | 1 |
| Benz, C | 1 |
| Hollander, C | 1 |
| Miller, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for flutamide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemci | 2002 |
Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Double-Blind Method; Female; | 2006 |
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Flutamide; | 1997 |
Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Double-Blind Method; | 1998 |
8 other studies available for flutamide and Pancreatic Neoplasms
| Article | Year |
|---|---|
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Topics: Adenocarcinoma; Biomarkers; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Ne | 2023 |
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Topics: Adenocarcinoma; Biomarkers; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Ne | 2023 |
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Topics: Adenocarcinoma; Biomarkers; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Ne | 2023 |
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Topics: Adenocarcinoma; Biomarkers; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Ne | 2023 |
Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Angiogenesis Inhibitors; Animals; Antibodies, M | 2007 |
Effect of flutamide on survival in patients with pancreatic cancer. Study needs to be repeated on a much larger scale.
Topics: Antineoplastic Agents, Hormonal; Flutamide; Humans; Pancreatic Neoplasms; Survival Analysis | 1999 |
Effect of flutamide on survival in patients with pancreatic cancer. Results are impressive.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Pancreatic Neoplasms | 1999 |
Effect of flutamide on survival in patients with pancreatic cancer. No recommendations can be made.
Topics: Antineoplastic Agents, Hormonal; Flutamide; Humans; Pancreatic Neoplasms; Randomized Controlled Tria | 1999 |
Androgen receptor-blocking agents: potential role in pancreatic cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Flutamide; Humans; Pancreatic Neoplasm | 2000 |
Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats.
Topics: Animals; Azaserine; Castration; Estradiol; Female; Flutamide; Male; Organ Size; Pancreatic Neoplasms | 1987 |
Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.
Topics: Aminoglutethimide; Animals; Azasteroids; Breast Neoplasms; Cell Cycle; Cell Line; Danazol; Dexametha | 1986 |